How cash flow works in a regenerative or longevity clinic
These clinics are usually built on cash-pay revenue: memberships, multi-month programs, packages and individual treatments. Some functional medicine practices also bill insurance for part of their services or give patients documentation to submit out of network. The result is revenue that is often recurring, but that depends heavily on patient retention and on how well new programs are received.
Memberships, programs and up-front costs
Membership revenue can be steady when retention is strong, and it can soften quickly when it is not. Longer programs may be paid up front or in installments, while the clinic carries the cost of lab testing, supplies, products and clinician time throughout. IV and peptide clinics often have frequent repeat visits, with ongoing supply and inventory purchases to match. Common uses of working capital include treatment-room buildouts, lab or diagnostic equipment, clinical hires, inventory and program marketing.
Why a bank may hesitate
This is a newer and evolving area of practice. Some banks may be less familiar with it, which can mean more questions, a longer review or a decision that a request falls outside their usual criteria.
Regulatory diligence
Because of the regulatory landscape, regulatory questions are part of the conversation for this specialty. According to the FDA consumer alert on regenerative medicine products, the only stem cell products that are FDA-approved for use in the United States consist of blood-forming stem cells derived from umbilical cord blood, approved for certain blood disorders, and there are currently no FDA-approved exosome products.
A funder may ask how your services and marketing comply with applicable FDA and state rules. PracticeFloat does not provide regulatory advice; questions about compliance belong with qualified healthcare regulatory counsel.
What PracticeFloat reviews
- Revenue history and bank-statement activity — the deposits reaching your business account and how steady they are.
- Time in operation.
- Existing advances and obligations already debiting the account.
- NSF and negative-balance history.
- Specialty and use of funds — what services the clinic offers and what the funds will be used for. A funder may ask how your services and marketing comply with applicable FDA and state rules.
- Owner guarantee — a personal guarantee from the owner is generally required.
The current published criteria are on the homepage under who qualifies; we keep them in one place so they stay accurate.
What you’ll need
You do not need everything to submit an inquiry. The practice review page lists what is typically requested:
- Recent business bank statements
- Existing funding contracts and payoff letters, if applicable
- Practice name and legal entity details
- Owner identification
How the process works
- Inquiry. No hard credit pull to submit an initial inquiry. An inquiry is not an application approval.
- Document review and underwriting. Later underwriting steps may include credit review, depending on the product and funder.
- Written offer. If one is available, it shows the amount, total repayment and payment schedule.
- Signing. Review the agreement, ideally with your accountant or attorney, and sign only if it works for you.
- Funding. Timing depends on verification and on the funding party.
PracticeFloat aims to respond within one business day of a complete inquiry — a target for a first reply, not a promise of a decision or funding. Terms, timing and the funding party depend on whether the transaction is funded by PracticeFloat or a partner funder. See how the process works.
Cost and repayment
Advances are commonly priced with a factor rate: the total repayment is the advance amount times the factor rate, fixed in the agreement. Repayment is made through scheduled daily or weekly ACH debits; the schedule and total repayment amount are disclosed in the agreement before signing.
Costs are typically higher than SBA or bank loans, and because the balance is repaid quickly, the annualized cost is higher than "factor cost divided by years" suggests. For example, an illustrative factor rate of 1.15 repaid over 6 months works out to roughly 57% on an annualized basis (illustrative, not PracticeFloat's pricing). This is educational, not a regulatory APR disclosure.
For membership-based clinics, compare the size of the scheduled payments with the revenue you can count on from current members, not with projected sign-ups.
Read how much practice funding costs, or model scenarios with the illustrative calculator (examples, not a quote).
When this may not be the right fit
- A service line's regulatory status is unclear. If you are unsure how a treatment or its marketing fits applicable FDA and state rules, resolve that with counsel before taking on fixed repayments that depend on revenue from it. None of the information on this page is regulatory or legal advice.
- The membership base is still building. If revenue depends on sign-ups you have not yet achieved, scheduled daily or weekly debits can strain cash. A smaller amount, or waiting until retention is established, may be more comfortable.
- The purchase is long-life equipment or real estate. Equipment financing or an SBA 504 loan is designed for long-life assets and is usually a better match (SBA: 504 loans).
- You have time and qualify for lower-cost credit. If a bank or SBA loan is available on reasonable terms, it usually costs less. See the SBA loan programs overview and our healthcare business loans guide.
Frequently asked questions
Does PracticeFloat work with stem cell, exosome or peptide clinics?
PracticeFloat reviews inquiries from regenerative medicine, longevity, functional medicine and IV and peptide clinics. Whether a transaction can be offered is determined during underwriting, and a funder may ask how your services and marketing comply with applicable FDA and state rules.
Why might a bank be hesitant about a longevity or regenerative clinic?
Some banks may be less familiar with newer, cash-pay specialties, which can mean more questions or a request that falls outside their usual criteria. If a bank or SBA loan is available on reasonable terms, it usually costs less than a working capital advance.
What does the FDA say about stem cell and exosome products?
According to the FDA consumer alert on regenerative medicine products, the only stem cell products that are FDA-approved for use in the United States consist of blood-forming stem cells derived from umbilical cord blood, and there are currently no FDA-approved exosome products.
Can PracticeFloat tell me whether my treatments or marketing are compliant?
No. PracticeFloat does not provide regulatory or legal advice. Questions about how your services and marketing fit applicable FDA and state rules should go to qualified healthcare regulatory counsel.
Our revenue is mostly memberships. How is that viewed?
Underwriting looks at the deposits that reach your business bank account, including membership payments, and how steady they are over time. How a particular clinic's revenue is weighed is determined during underwriting.